Abstract
Unlike conventional Coronavirus 2019 (COVID-19) vaccines, intranasal vaccines display a superior advantage because the nasal mucosa is often the initial site of infection. Preclinical and clinical studies concerning intranasal immunization elicit high neutralizing antibody generation and mucosal IgA and T cell responses that avoid severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in both; the upper and lower respiratory tract. A nasal formulation is non-invasive with high appeal to patients. Intranasal vaccines enable self-administration and can be designed to survive at ambient temperatures, thereby simplifying logistical aspects of transport and storage. In this review, we provide an overview of nasal vaccines with a focus on formulation development as well as ongoing preclinical and clinical studies for SARS-CoV-2 intranasal vaccine products.
Original language | English |
---|---|
Pages (from-to) | 2619-2636 |
Number of pages | 18 |
Journal | Drug Discovery Today |
Volume | 26 |
Issue number | 11 |
Early online date | 29 Jul 2021 |
DOIs | |
Publication status | Published - 01 Nov 2021 |
Bibliographical note
Funding Information:Figs. 1 and 2 were prepared using templates from BioRender.com. A.K.P. would like to thank the Department of Science & Technology (DST) INSPIRE program of the Ministry of Science & Technology, Government of India, for providing her fellowship. V.B.P. would like to acknowledge DBT BIRAC COVID-19 Research Consortium, Government of India, for her grant to work toward the development of an intranasal mucosal vaccine for COVID-19 infection (BT/PR40394/COV/140/1/2020).
Funding Information:
Anjali Pandya is a recipient of a doctoral fellowship at the Institute of Chemical Technology, Mumbai, India, awarded by the Department of Science and Technology (DST) - Innovation in Science Pursuit for Inspired Research (INSPIRE), Government of India, for research on oral protein and peptide delivery,.
Publisher Copyright:
© 2021 Elsevier Ltd
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
Keywords
- Antigen-presenting cells (APCs)
- COVID-19
- Dendritic cells
- Nasal spray
- Nasal vaccine
- SARS-CoV-2
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery